loading page

The kidney conundrum: Evaluating the value of ifosfamide in cancer therapeutics.
  • +8
  • Marcio José Concepción-Zavaleta,
  • Juan Eduardo Quiroz-Aldave,
  • María del Carmen Durand-Vásquez,
  • Freddy Shanner Chávez-Vásquez,
  • Alexandra Noelia Rodríguez-Angulo,
  • Sonia Elizabeth Gonzáles-Saldaña,
  • Carlos César Alcalde-Loyola,
  • Julia Cristina Coronado-Arroyo,
  • Francisca Elena Zavaleta-Gutiérrez,
  • Luis Alberto Concepción-Urteaga,
  • Juan Carlos Haro-Varas
Marcio José Concepción-Zavaleta
Universidad Cientifica del Sur

Corresponding Author:[email protected]

Author Profile
Juan Eduardo Quiroz-Aldave
Hospital de Apoyo Chepén
Author Profile
María del Carmen Durand-Vásquez
Hospital de Apoyo Chepén
Author Profile
Freddy Shanner Chávez-Vásquez
Hospital Maria Auxiliadora
Author Profile
Alexandra Noelia Rodríguez-Angulo
Universidad Privada Antenor Orrego Facultad de Medicina Humana
Author Profile
Sonia Elizabeth Gonzáles-Saldaña
Hospital de Apoyo Chepén
Author Profile
Carlos César Alcalde-Loyola
Hospital Leoncio Prado
Author Profile
Julia Cristina Coronado-Arroyo
Hospital Nacional Edgardo Rebagliati Martins
Author Profile
Francisca Elena Zavaleta-Gutiérrez
Hospital Belen De Trujillo
Author Profile
Luis Alberto Concepción-Urteaga
Hospital Regional Docente de Trujillo
Author Profile
Juan Carlos Haro-Varas
Instituto Nacional de Enfermedades Neoplasicas
Author Profile


Introduction: Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. Methods: A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Results: Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. An analysis of reported cases in the literature showed an average age of 29 years, with no gender predominance. In oncology patients treated with ifosfamide, a mortality rate of 13% has been observed. Currently, no fully effective therapeutic strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Conclusions: Ifosfamide exhibits a broad spectrum of antitumoral activity but may induce nephrotoxicity, adversely affecting the prognosis of oncology patients. Therefore, a thorough evaluation of the risks and benefits associated with its use is necessary.